Close menu




March 3rd, 2021 | 05:50 CET

ProSiebenSat.1 Media, Aspermont, Alibaba: Digital media as a multiplier opportunity

  • Investments
Photo credits: pixabay.com

When investors think of the media industry, they often still have stories of declining circulation and dwindling audiences in the back of their minds. But they often forget that media companies have long since made a virtue of necessity and gone digital. It is precisely when traditional media companies' quality meets modern digital groups' possibilities that great opportunities arise for investors. We present three shares.

time to read: 2 minutes | Author: Nico Popp
ISIN: DE000PSM7770 , AU000000ASP3 , US01609W1027

Table of contents:


    ProSiebenSat.1 Media: More dating than TV

    The ProSiebenSat.1 Media share is an old acquaintance on the German trading floor. But while the stock stood primarily for two TV stations for many years, today the Company is more than that. ProSiebenSat.1 is a big player in online dating. JP Morgan analysts recently emphasized that ProSiebenSat.1's stake in ParshipMeet is worth more than previously thought. The analysts, therefore, describe the share as a "key pick" among European media stocks.

    Over the past year, the share price performance shows a steep upward trend and a return of more than 60%. Given this development, the question arises to what extent ProSiebenSat.1 stock can still be moderately valued. Currently, the market capitalization is just over EUR 3 billion. As earnings are expected to be higher in 2021, this also justifies a rising share price. However, the ProSiebenSat.1 share is no longer an insider tip.

    Aspermont: Major investors get on board

    The shares of the Australian media Group Aspermont, on the other hand, are much less well known - although the Company stands for renowned titles such as Mining Journal and Mining Magazine, both of which have been published without interruption for more than a hundred years. There are numerous other brands and services that Aspermont offers its customers. After challenging years, the Company has gone digital and now distributes 95% of its content on digital channels. The customers: Companies from around the world working in, or supplying to, the mining, energy, and agricultural sectors.

    Over the years, Aspermont has built up a network of over seven million contacts, all of which are decision-makers in the respective companies. Aspermont intends to use these contacts to sell additional services in the future. Up to now, Aspermont has been quite accommodating toward business customers and has even turned a blind eye when several employees used access at the same time. In the long term, this could prove to be a smart move and help to bring new products to customers or adapt established subscriptions to actual usage. Aspermont sees potential in online commerce platforms, blockchain and e-learning.

    Recently, the Company announced a capital increase at AUD 0.03 per share, for which trading on its home exchange in Australia was suspended for one day. The move is backed by a single institutional investor from Germany and flushes AUD 3 million into the Company's coffers. In total, the Company now has more than AUD 7 million in its coffers and plans to invest the funds in further growth. Institutional investor confidence should help further publicize the investment story around Aspermont and stabilize the share price at current levels. With a market capitalization of less than EUR 30 million, the stock is a real insider's tip.

    Alibaba remains uncertain

    In contrast, the Alibaba share is well-known around the globe. The Company is considered Asia's Amazon and is just as broadly positioned. A few months ago, the canceled IPO of the fintech subsidiary Ant Group caused a furor. What was planned to be the largest IPO ever had to be postponed under pressure from Beijing. The appearance of Alibaba founder Jack Ma was seemingly too self-confident for the powers that be in Beijing. In the meantime, Ant Group has restructured itself and wants to manage the IPO in a second attempt. The hiccups have not been good for the parent Company Alibaba's share price: over one year, the investment return is only 6.3%. The share remains a hot topic.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?

    Read

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.

    Read